TNF Inhibitor denied for failing step therapy by OptumRx?

Adalimumab biosimilar preferred (Cyltezo / Hyrimoz / Adalimumab-adaz). Step therapy from biosimilar. Self-administered — Part D / pharmacy benefit.

OptumRx Continuity of Care provisions for >180-day stable patients. ACR 2019 anti-non-medical-switching position. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241).

## Why OptumRx Denied Your TNF Inhibitor Under Step Therapy

OptumRx uses step-therapy (also called "fail-first") protocols for TNF inhibitors. These protocols require patients to try and document inadequate response to one or more less-expensive preferred agents before a TNF inhibitor will be authorized. The specific sequence of required prior agents is defined in OptumRx's clinical coverage policy and may include conventional disease-modifying drugs, other biologic classes, or biosimilar versions of the requested agent. A step-therapy denial means the plan believes you have not yet completed the required sequence — or that the documentation submitted did not adequately demonstrate failure or intolerance of the required step agents.

## Why This Denial Is Frequently Overturned

Step-therapy denials are overturned when the patient has already tried the required agents and the documentation proves it, or when a required step agent is clinically contraindicated. Incomplete prior-authorization submissions frequently omit dates, outcomes, or the clinical reason for discontinuation — all of which the plan needs to verify step completion. A complete appeal that provides the full medication history with dates and documented outcomes resolves most step-therapy denials at the internal level.

Many states have also enacted step-therapy reform laws that prohibit plans from requiring a patient to restart a step sequence they already completed on a prior plan, or from applying step therapy when the prescriber certifies that the required agent would be contraindicated or clinically harmful. Confirm whether your state's law applies to your plan type.

## Federal Appeal Rights

Under ERISA §503, you are entitled to the plan's full claim file and a plain-language explanation of every step-therapy criterion that was not satisfied. Under ACA §2719, a step-therapy denial is subject to independent external review if the internal appeal fails. The external-review window is generally 4 months from the date of the adverse determination; expedited review (72 hours) is available when your health would be seriously jeopardized by delay.

## Concrete Appeal Steps and Timeline

1. Request the OptumRx clinical coverage policy for this TNF inhibitor and identify every required step agent. 2. Collect the medication history from your chart documenting each required step agent that was tried. 3. File a Level 1 internal appeal within the deadline on your denial letter, with the complete documentation package. 4. If the internal appeal is denied, request external review before the 4-month window closes. 5. If your state has a step-therapy override law, cite it explicitly in your appeal letter.

## Documentation to Gather

• Complete medication history: For each required step agent — name, start date, stop date, doses as documented in the chart, and the treating physician's documented reason for discontinuation (inadequate response, adverse effect, or contraindication).
• Contraindication documentation: If any required step agent is contraindicated for this patient, provide the chart entry or specialist note establishing why.
• Disease-progression records: Lab results, imaging, clinical assessments, or functional measures showing ongoing or worsening disease activity during or after required prior therapies.
• Prescriber medical-necessity letter: A letter from your physician explaining that step-therapy requirements have been met or are inapplicable, describing the clinical course in detail, and citing the applicable professional society guideline organization.
• State step-therapy law citation: If applicable, include the statute or regulation requiring the plan to grant an exception.

## Criteria-Mapping Structure

Obtain the exact text of OptumRx's step-therapy criteria for this drug. Create a table: criterion verbatim on the left; chart documentation (medication name, start/stop dates, outcome, record source) on the right. If a criterion requires prior use of a specific drug class, name the class from the policy and match it to the corresponding entry in the medication history. This structure makes step completion undeniable and is the most effective format for this denial type.